158 related articles for article (PubMed ID: 38700360)
21. Clinical presentation, diagnostic findings and outcome in dogs diagnosed withpresumptive spinal-only meningoen-cephalomyelitis of unknown origin.
Cornelis I; Volk HA; Van Ham L; De Decker S
J Small Anim Pract; 2017 Mar; 58(3):174-182. PubMed ID: 28267222
[TBL] [Abstract][Full Text] [Related]
22. Long-term immunosuppressive therapy with cyclosporine plus prednisolone for necrotizing meningoencephalitis in a Pekingese dog.
Jung DI; Kim JW; Park HM
J Vet Med Sci; 2012 Jun; 74(6):765-9. PubMed ID: 22214856
[TBL] [Abstract][Full Text] [Related]
23. Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology.
Early PJ; Crook KI; Williams LM; Davis EG; Muñana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2017 Aug; 40(4):411-414. PubMed ID: 27641693
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the use of cytosine arabinoside for treatment for recurrent canine steroid-responsive meningitis-arteritis.
Günther C; Steffen F; Alder DS; Beatrice L; Geigy C; Beckmann K
Vet Rec; 2020 Jul; 187(1):e7. PubMed ID: 33638531
[TBL] [Abstract][Full Text] [Related]
25. Clinical features, treatment, and outcome of juvenile dogs with meningoencephalitis of unknown etiology.
Galer J; Forward AK; Hughes J; Crawford AH; Behr S; Cherubini GB; Cornelis I; Royaux E
J Vet Intern Med; 2024 Jun; ():. PubMed ID: 38932495
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005-2011).
Barnoon I; Shamir MH; Aroch I; Bdolah-Abram T; Srugo I; Konstantin L; Chai O
J Vet Emerg Crit Care (San Antonio); 2016; 26(1):116-24. PubMed ID: 26458162
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein concentration has limited value in the diagnosis of meningoencephalitis of unknown origin in dogs.
Cavalerie R; Santos ACD; Leonardi H; Blond L; Beurlet S; Dumont R; Piazza S
J Am Vet Med Assoc; 2024 Apr; 262(4):481-488. PubMed ID: 38266391
[TBL] [Abstract][Full Text] [Related]
28. Suspected drug-induced infiltrative lung disease culminating in acute respiratory failure in a dog treated with cytarabine and prednisone.
Hart SK; Waddell L
J Vet Emerg Crit Care (San Antonio); 2016 Nov; 26(6):844-850. PubMed ID: 27062671
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Pastina B; Early PJ; Bergman RL; Nettifee J; Maller A; Bray KY; Waldron RJ; Castel AM; Munana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2018 Oct; 41(5):638-643. PubMed ID: 29761906
[TBL] [Abstract][Full Text] [Related]
30. Postencephalitic epilepsy in dogs with meningoencephalitis of unknown origin: Clinical features, risk factors, and long-term outcome.
Kaczmarska A; José-López R; Czopowicz M; Lazzerini K; Leblond G; Stalin C; Gutierrez-Quintana R
J Vet Intern Med; 2020 Mar; 34(2):808-820. PubMed ID: 31990104
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Levitin HA; Foss KD; Li Z; Reinhart JM; Hague DW; Fan TM
J Vet Pharmacol Ther; 2021 Sep; 44(5):696-704. PubMed ID: 34080695
[TBL] [Abstract][Full Text] [Related]
32. Toxicity of cytarabine constant rate infusion in dogs with high-grade non-Hodgkin lymphoma with bone marrow or central nervous system involvement.
Guillen A; Finotello R; Wynne P; Harper A; Killick D; Amores-Fuster I; Blackwood L
Aust Vet J; 2020 Mar; 98(3):69-78. PubMed ID: 31769013
[TBL] [Abstract][Full Text] [Related]
33. Prognosis in meningoencephalitis of unknown origin in dogs: Risk factors associated with survival, clinical relapse, and long-term disability.
Gonçalves R; De Decker S; Walmsley G; Maddox TW
J Vet Intern Med; 2024; 38(3):1583-1590. PubMed ID: 38483069
[TBL] [Abstract][Full Text] [Related]
34. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
35. Opioid-sparing effect of a medetomidine constant rate infusion during thoraco-lumbar hemilaminectomy in dogs administered a ketamine infusion.
Pascal M; Allison A; Kaartinen J
Vet Anaesth Analg; 2020 Jan; 47(1):61-69. PubMed ID: 31791743
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
37. Ciclosporin use in multi-drug therapy for meningoencephalomyelitis of unknown aetiology in dogs.
Adamo PF; Rylander H; Adams WM
J Small Anim Pract; 2007 Sep; 48(9):486-96. PubMed ID: 17617166
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on meningoencephalomyelitis of unknown origin.
Coates JR; Jeffery ND
Vet Clin North Am Small Anim Pract; 2014 Nov; 44(6):1157-85. PubMed ID: 25239815
[TBL] [Abstract][Full Text] [Related]
39. A shortened whole brain radiation therapy protocol for meningoencephalitis of unknown origin in dogs.
Herzig R; Beckmann K; Körner M; Steffen F; Rohrer Bley C
Front Vet Sci; 2023; 10():1132736. PubMed ID: 37020978
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for 1-week survival in dogs diagnosed with meningoencephalitis of unknown aetiology.
Cornelis I; Volk HA; Van Ham L; De Decker S
Vet J; 2016 Aug; 214():91-5. PubMed ID: 27387733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
